Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer

Vijay Patil, Sravan Kumar,Vanita Noronha,Nandini Menon,Kavita Prakash Nawale,Mitali Alone, Gopichand Waratkar,Sachin Dhumal,Atanu Bhattacharjee,Kumar Prabhash

Journal of Clinical Oncology（2022）

引用 0|浏览2

暂无评分

摘要

•Cabazitaxel had inferior PFS in comparison to docetaxel.•Cabazitaxel has inferior OS in comparison to docetaxel.•Age and site of disease influence OS.

查看译文

关键词

Cabazitaxel,Docetaxel,Head and neck cancer,Palliative,Long term,Second Line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要